Jinxin Fertility Group Limited (abbreviated as “JXR”) reported that it repurchased 1.70 million ordinary shares on 11 November 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were bought at prices between HKD 2.265 and HKD 2.325, with a volume-weighted average of HKD 2.28, resulting in a total consideration of HKD 3.87 million.
The buyback reduced the company’s issued share capital (excluding treasury shares) by 0.0646 % to 2.62 billion shares, while increasing the treasury-share balance to 81.77 million. Total issued shares remained unchanged at 2.71 billion.
Under the general mandate approved on 25 June 2026, JXR is authorised to repurchase up to 262.51 million shares. Cumulative repurchases since the mandate now stand at 94.32 million shares, representing 3.59 % of the share count on the mandate date. All shares bought back to date, including 92.47 million shares acquired earlier in 2026 that are awaiting cancellation, are being held as treasury shares.
Pursuant to Hong Kong Listing Rules, JXR is subject to a 30-day moratorium on issuing new shares or selling/transferring treasury shares, effective until 11 December 2026.
Comments